Mutual ATRaction: Assessing synergy of berzosertib with sacituzumab govitecan.

A phase 1 trial of the novel combination of the ATR inhibitor, berzosertib, plus the antibody-drug conjugate, sacituzumab govitecan, in patients with heavily pre-treatment tumors demonstrated some anti-tumor activity and no dose-limiting toxicities. This represents a new treatment paradigm which will be further explored in a phase 2 setting.